Insider trades
Mark E. Bunnage, Chief Officer of Vertex Pharmaceuticals VRTX, has filed 0 purchases and 5 sales on the open market. Over the past 12 months that comes to a net sale of $3M. The latest trade was on 05/15.
Mark E. Bunnage
EVP, Chief Scientific Officer
- Company
- Vertex Pharmaceuticals VRTX
- First filing
- 26/02/26
- Trades
- 10 trades
- Buys / sales
- 0 / 5
- 12-month net buying
- −$3M
- Last trade
- 05/15
Trading activity
Transactions
| Trade type | |||||||
|---|---|---|---|---|---|---|---|
| Open-market sale10b5-1 plan | 05/15 | 05/19 | 33 sh | $453.45 | $14,963.85 | −0.5% | |
| Open-market sale10b5-1 plan | 02/25 | 02/26 | 620 sh | $486.35 | $301,537 | −7.8% | |
VRTX | Open-market sale10b5-1 plan | 02/17–02/18 | 02/19 | 3,619 sh2 trades | $484.31avg. | $1,752,703.78 | −29.9% |
| Open-market sale10b5-1 plan | 02/11 | 02/12 | 2,021 sh | $460.43 | $930,529.03 | −13.5% |